FEATURED EDITORIAL
DiaMedica is testing a synthetic, first-in-class recombinant human kallikrein‑1 (rhKLK1) biologic in Phase 2 clinical trials to treat preeclampsia, which remains one of the most dangerous complications of pregnancy.
- GLP-1 And Addiction: Mechanism, Missteps, And What Comes Next
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- GLP-1 Agonists In Addiction: Rationale And Drug Development
- Why Rare Cancers Are Often Left Behind In Drug Discovery
- Why Cell And Gene Therapies Break After Early Success
- AI: The Inflection Point In Retinal Drug Discovery, Development, And Delivery
- AI, Digitalization, And In Vivo Programming Redefine Cell And Gene Therapy
FEATURED APPLICATION CONTENT
-
Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.
-
Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.
-
High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.
-
A streamlined RNA‑seq workflow enables high‑throughput gene expression profiling directly from cell lysates, reducing cost and complexity. See how this approach accelerates lead selection.
-
Accurate serial dilutions depend on more than calculations. Learn how mixing, tip handling, and workflow consistency influence accuracy, as well as how small adjustments can improve reproducibility.
-
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
- From Urine-Derived To Recombinant Precision: KLK1 Reimagined For Preeclampsia
- Next‑Generation Omics: Latest Insights From A Growing Field
- 5 Takeaways From The Boston Open Science & Innovation Forum
- Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Creatv Bio Opens CLIA-Certified Laboratory To Support Oncology Drug Development
- Nexentis Technologies Announces Optimization Of Hit Molecule At MitoCareX Bio Representing Key Drug Discovery Milestone
- AndzonBio2, The ALBORADA Drug Discovery Institute At The University Of Cambridge And Cambridge Enterprise Announce A Collaboration To Develop First-In-Class Therapeutics For Neuroinflammation
- Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery
- Government's Sovereign AI Invests In British-Founded AI Company Redefining How Medicines Are Designed
- Ribo Announces Strategic Collaboration With Insilico Medicine To Accelerate siRNA Drug Development Driven By AI
- Kelun-Biotech Receives Investigational New Drug Approval From CDE For SKB118, A PD-1 x VEGF Bispecific Antibody
- Partner Therapeutics Announces FDA Approval Of BIZENGRI® (Zenocutuzumab-zbco) For NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt Of FDA Commissioner's National Priority Voucher
- ACROBiosystems Launches Global License Solution Upgrade For HEK293 Functional Cell Lines, Streamlining Compliance To Accelerate Biopharmaceutical R&D
- Harbour BioMed Announces U.S. FDA IND Clearance For HBM7004 For The Treatment Of Advanced Solid Tumors
ARCHIVED NEWSLETTER
- 05.02.26 -- Drug Discovery Online Best Of April
- 04.29.26 -- Master pipetting, PCR, and NGS for cell and gene workflows.
- 04.28.26 -- Structural Biology Wages War On HIV And The Pandemics Of Tomorrow
- 04.24.26 -- Why Open-Source AI Models Matter For Computational Drug Discovery
- 04.14.26 -- Next Generation Omics: Latest Insights From A Growing Field
